Please login to the form below

Not currently logged in
Email:
Password:

aflibercept

This page shows the latest aflibercept news and features for those working in and with pharma, biotech and healthcare.

After Lucentis setback, Novartis trumpets data on follow-up drug

After Lucentis setback, Novartis trumpets data on follow-up drug

The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD),

Latest news

  • NHS wins legal fight with pharma over off-label Avastin NHS wins legal fight with pharma over off-label Avastin

    Bayer's Eylea (aflibercept) and Novartis' Lucentis (ranibizumab) are among the top selling drugs in England, number 2 and number 5 in the top ten medicines by spending in the

  • Allergan’s abicipar matches AMD blockbuster Lucentis in phase III Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

    Both studies will continue for another year. Lucentis – sold by Roche in the US and Novartis in Europe and other markets – and Regeneron’s Eylea (aflibercept) currently dominate the wet AMD

  • Regeneron’s Dupixent and Praluent falls short Regeneron’s Dupixent and Praluent falls short

    Regeneron needs the two drugs, both partnered with Sanofi, to ramp up sales quickly before its ophthalmic blockbuster Eylea (aflibercept) - which generates nearly two-thirds of its revenues - starts to lose

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    Novartis. Eylea (aflibercept) – which is partnered with Bayer – is the market leader in AMD with sales of $2.73bn in the first nine months of the year, but is facing the ... The studies assessed two different doses of nesvacumab in combination with

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    Stivarga is a key component among a new generation of pharma products - along with cancer drug Xofigo (radium-223 dichloride), anticoagulant Xarelto (rivaroxaban), ophthalmic therapy Eylea (aflibercept) and pulmonary arterial hypertension

More from news
Approximately 17 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration &licence. $134. Regeneron/ Bayer. Ophthalmology combination therapy: nesvacumab (Ang2 antibody) and aflibercept (VEGF trap).

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    In addition fellow German firm Bayer criticised IQWiG's assessment of trial designs after the HTA body deemed data for eye drug Eylea (aflibercept) unsuitable in order to judge its

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics